196 related articles for article (PubMed ID: 36915230)
1. Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4/CyclinD1-pRB-E2F1 pathway.
Wang J; Zhang J; Ma Q; Zhang S; Ma F; Su W; Zhang T; Xie X; Di C
J Cell Mol Med; 2023 Apr; 27(7):991-1005. PubMed ID: 36915230
[TBL] [Abstract][Full Text] [Related]
2. Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population.
Zeng Z; Tu J; Cheng J; Yao M; Wu Y; Huang X; Xie X; Zhang X; Lu F; Chen X
Tumour Biol; 2015 Sep; 36(9):6891-900. PubMed ID: 25851350
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation.
Wang J; Su W; Zhang T; Zhang S; Lei H; Ma F; Shi M; Shi W; Xie X; Di C
Cell Death Dis; 2023 Apr; 14(4):244. PubMed ID: 37024471
[TBL] [Abstract][Full Text] [Related]
4. CCND1 Splice Variant as A Novel Diagnostic and Predictive Biomarker for Thyroid Cancer.
Jeon S; Kim Y; Jeong YM; Bae JS; Jung CK
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30428594
[TBL] [Abstract][Full Text] [Related]
5. Bisphenol S promotes the cell cycle progression and cell proliferation through ERα-cyclin D-CDK4/6-pRb pathway in MCF-7 breast cancer cells.
Lin Z; Zhang X; Zhao F; Ru S
Toxicol Appl Pharmacol; 2019 Mar; 366():75-82. PubMed ID: 30684532
[TBL] [Abstract][Full Text] [Related]
6. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1.
Yu CP; Yu JC; Sun CA; Tzao C; Ho JY; Yen AM
Breast Cancer Res Treat; 2008 Jan; 107(1):95-102. PubMed ID: 18043898
[TBL] [Abstract][Full Text] [Related]
7. MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and CCND1.
Bao C; Chen J; Chen D; Lu Y; Lou W; Ding B; Xu L; Fan W
Cell Death Dis; 2020 Aug; 11(8):618. PubMed ID: 32796817
[TBL] [Abstract][Full Text] [Related]
8. AA genotype of cyclin D1 G870A polymorphism increases breast cancer risk: Findings of a case-control study and meta-analysis.
Akhter N; Alzahrani FA; Dar SA; Wahid M; Sattar RSA; Hussain S; Haque S; Ansari SA; Jawed A; Mandal RK; Almalki S; Alharbi RA; Husain SA
J Cell Biochem; 2019 Oct; 120(10):16452-16466. PubMed ID: 31243808
[TBL] [Abstract][Full Text] [Related]
9. CCND1 G870A polymorphism with altered cyclin D1 transcripts expression is associated with the risk of glioma in a Chinese population.
Chen X; Zhao T; Li L; Xu C; Zhang X; Tse V; Zhang T; Liu X; Lu F
DNA Cell Biol; 2012 Jun; 31(6):1107-13. PubMed ID: 22304571
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of cyclinD1 amplification and the co-alteration of cyclinD1/pRb/ppRb in patients with esophageal squamous cell carcinoma.
Wang MT; Chen G; An SJ; Chen ZH; Huang ZM; Xiao P; Ben XS; Xie Z; Chen SL; Luo DL; Tang JM; Lin JY; Zhang XC; Wu YL
Dis Esophagus; 2012; 25(7):664-70. PubMed ID: 22150974
[TBL] [Abstract][Full Text] [Related]
11. Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer.
Bedewy AM; Mostafa MH; Saad AA; El-Maghraby SM; Bedewy MM; Hilal AM; Kandil LS
J BUON; 2013; 18(1):227-38. PubMed ID: 23613410
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis involving 23,998 subjects.
Yang J; Liu H; Lu S; Gao M; Du Q; Tang SC
Oncol Res; 2011; 19(12):519-25. PubMed ID: 22812184
[TBL] [Abstract][Full Text] [Related]
13. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.
Grillo M; Bott MJ; Khandke N; McGinnis JP; Miranda M; Meyyappan M; Rosfjord EC; Rabindran SK
Breast Cancer Res Treat; 2006 Jan; 95(2):185-94. PubMed ID: 16319987
[TBL] [Abstract][Full Text] [Related]
14. Effect of extracts from Radix Ginseng, Radix Notoginseng and Rhizoma Chuanxiong on delaying aging of vascular smooth muscle cells in aged rats.
Tao LL; Lei Y; Wang GL; Zhu LQ; Wang Y
Chin J Integr Med; 2012 Aug; 18(8):582-90. PubMed ID: 22855034
[TBL] [Abstract][Full Text] [Related]
15. The CDK4-pRB-E2F1 pathway controls insulin secretion.
Annicotte JS; Blanchet E; Chavey C; Iankova I; Costes S; Assou S; Teyssier J; Dalle S; Sardet C; Fajas L
Nat Cell Biol; 2009 Aug; 11(8):1017-23. PubMed ID: 19597485
[TBL] [Abstract][Full Text] [Related]
16. microRNA-16-5p enhances radiosensitivity through modulating Cyclin D1/E1-pRb-E2F1 pathway in prostate cancer cells.
Wang F; Mao A; Tang J; Zhang Q; Yan J; Wang Y; Di C; Gan L; Sun C; Zhang H
J Cell Physiol; 2019 Aug; 234(8):13182-13190. PubMed ID: 30536619
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity.
Takano Y; Takenaka H; Kato Y; Masuda M; Mikami T; Saegusa M; Okayasu I
J Cancer Res Clin Oncol; 1999; 125(8-9):505-12. PubMed ID: 10480344
[TBL] [Abstract][Full Text] [Related]
18. Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68.
Paronetto MP; Cappellari M; Busà R; Pedrotti S; Vitali R; Comstock C; Hyslop T; Knudsen KE; Sette C
Cancer Res; 2010 Jan; 70(1):229-39. PubMed ID: 20028857
[TBL] [Abstract][Full Text] [Related]
19. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers.
Grieu F; Malaney S; Ward R; Joseph D; Iacopetta B
Anticancer Res; 2003; 23(5b):4257-9. PubMed ID: 14666635
[TBL] [Abstract][Full Text] [Related]
20. Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b).
Rojas P; Benavides F; Blando J; Perez C; Cardenas K; Richie E; Knudsen ES; Johnson DG; Senderowicz AM; Rodriguez-Puebla ML; Conti CJ
Mol Carcinog; 2009 Jun; 48(6):508-16. PubMed ID: 18942117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
